

# Herbert Pang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8733133/publications.pdf>

Version: 2024-02-01

87  
papers

2,450  
citations

304743

22  
h-index

206112

48  
g-index

87  
all docs

87  
docs citations

87  
times ranked

4124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	1.6	362
2	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	10.7	362
3	Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Safety Profile and Management of Adverse Events. <i>Seminars in Oncology</i> , 2006, 33, S26-S34.	2.2	165
4	Integrating the Anti-VEGF-A Humanized Monoclonal Antibody Bevacizumab with Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, S62-S68.	2.3	131
5	Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3002.	1.6	129
6	Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival. <i>Annals of Surgical Oncology</i> , 2001, 8, 801-806.	1.5	122
7	Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas. <i>Annals of Surgical Oncology</i> , 1999, 6, 38-45.	1.5	99
8	Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). <i>Clinical Cancer Research</i> , 2013, 19, 6957-6966.	7.0	95
9	Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 704-704.	1.6	92
10	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018, 110, 638-648.	6.3	90
11	Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. <i>Investigational New Drugs</i> , 2018, 36, 683-695.	2.6	75
12	Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. <i>Cancer Medicine</i> , 2013, 2, 234-242.	2.8	64
13	Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 402-402.	1.6	49
14	Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 355-364.	2.3	33
15	Association of TGF- $\beta$ 2 responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF- $\beta$ 2 receptor type I (TGFBR1) inhibitor in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3031-3031.	1.6	32
16	The McCaVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). <i>Oncologist</i> , 2020, 25, e451-e459.	3.7	30
17	A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4000-4000.	1.6	30
18	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 676-676.	1.6	30

#	ARTICLE	IF	CITATIONS
19	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 938-946.	6.4	29
20	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. <i>Clinical Cancer Research</i> , 2020, 26, 1288-1296.	7.0	29
21	Modulation of circulating protein biomarkers following TRC 105 (anti-Endoglin antibody) treatment in patients with advanced cancer. <i>Cancer Medicine</i> , 2014, 3, 580-591.	2.8	27
22	Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4520.	1.6	25
23	Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1048-1056.	4.1	22
24	Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4010-4017.	7.0	22
25	Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. <i>International Journal of Cancer</i> , 2018, 142, 1322-1331.	5.1	20
26	Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 564.	7.1	19
27	Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2248-2256.	4.1	17
28	Targeted therapy for gastrointestinal (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 653-653.	1.6	17
29	Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-343.	1.6	17
30	Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 348-348.	1.6	17
31	Final results of the McCaVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3539-3539.	1.6	13
32	A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard). <i>Oncologist</i> , 2012, 17, 937-946.	3.7	11
33	A Phase Ib study of ruxolitinib + gemcitabine & nab-paclitaxel in patients with advanced solid tumors. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2399-2407.	2.0	11
34	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	7.0	11
35	Phase I study of receptor tyrosine kinase (RTK) inhibitor, MCD265, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2589-2589.	1.6	10
36	Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 492-492.	1.6	10

#	ARTICLE	IF	CITATIONS
37	New Combinations in Metastatic Colorectal Cancer: What Are Our Expectations?. <i>Oncologist</i> , 2005, 10, 320-322.	3.7	9
38	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 391-397.	0.5	9
39	Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3597-3597.	1.6	9
40	Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3520-3520.	1.6	8
41	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN± ± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	7.0	8
42	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3535-3535.	1.6	6
43	Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9073-9073.	1.6	6
44	MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS11111-TPS11111.	1.6	5
45	JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4147-TPS4147.	1.6	5
46	Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin± paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5521-5521.	1.6	5
47	A phase 1, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 x CD3 DART molecule, in patients with relapsed/refractory metastatic colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3628-TPS3628.	1.6	5
48	Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6086-6086.	1.6	5
49	Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3548-3548.	1.6	4
50	Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA11511-LBA11511.	1.6	4
51	Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA11511-LBA11511.	1.6	4
52	Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2549-2549.	1.6	4
53	Paracrine wnt-1 <sup>2</sup> -catenin signaling inhibition as a strategy to enhance the efficacy of anti-PD-1 antibody (Ab) therapy in a transgenic model of melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3053-3053.	1.6	4
54	Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 657-657.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database.. Journal of Clinical Oncology, 2017, 35, 3582-3582.	1.6	4
56	Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. Clinical Trials, 2021, 18, 51-60.	1.6	3
57	Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).. Journal of Clinical Oncology, 2013, 31, 4042-4042.	1.6	3
58	Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.. Journal of Clinical Oncology, 2013, 31, 3533-3533.	1.6	2
59	First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.. Journal of Clinical Oncology, 2014, 32, 2532-2532.	1.6	2
60	Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. Journal of Clinical Oncology, 2014, 32, 3578-3578.	1.6	2
61	Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).. Journal of Clinical Oncology, 2016, 34, e15013-e15013.	1.6	2
62	Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer.. Journal of Clinical Oncology, 2016, 34, 630-630.	1.6	2
63	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	1.6	1
64	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 490-490.	1.6	1
65	X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 687-687.	1.6	1
66	Correlation of pre- and post-induction plasma mutant allele fraction with progression-free survival (PFS) in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, e15118-e15118.	1.6	1
67	STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, TPS3652-TPS3652.	1.6	1
68	HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in <i>RAS</i> -wt advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 2015, 33, 3583-3583.	1.6	1
69	Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).. Journal of Clinical Oncology, 2017, 35, 4522-4522.	1.6	1
70	Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.. Journal of Clinical Oncology, 2017, 35, 11546-11546.	1.6	1
71	Topical sildenafil in the treatment of hand-foot syndrome and hand-foot skin reaction: A retrospective study.. Journal of Clinical Oncology, 2018, 36, e22095-e22095.	1.6	1
72	A phase I/II study of capecitabine (Cape), oxaliplatin (Ox), panitumumab (Pmab), and external beam radiation therapy (RT) for patients with esophagogastric carcinoma (EC).. Journal of Clinical Oncology, 2012, 30, 68-68.	1.6	0

#	ARTICLE	IF	CITATIONS
73	MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study.. Journal of Clinical Oncology, 2012, 30, 3039-3039.	1.6	0
74	Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients.. Journal of Clinical Oncology, 2012, 30, 3042-3042.	1.6	0
75	Efficacy and safety of bevacizumab in metastatic colorectal cancer (mCRC): Pooled analysis from randomized controlled trials (RCTs).. Journal of Clinical Oncology, 2012, 30, 3614-3614.	1.6	0
76	Effectiveness of bevacizumab (BV) beyond disease progression in metastatic colorectal cancer (mCRC): Analyses by sex in the ARIES observational cohort study (OCS).. Journal of Clinical Oncology, 2013, 31, 514-514.	1.6	0
77	Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).. Journal of Clinical Oncology, 2013, 31, 11011-11011.	1.6	0
78	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2574-2574.	1.6	0
79	Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.. Journal of Clinical Oncology, 2014, 32, 3537-3537.	1.6	0
80	Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies.. Journal of Clinical Oncology, 2015, 33, 84-84.	1.6	0
81	Characteristics of long- versus short-surviving patients (Pts): An analysis of the ARIES Observational Cohort Study (OCS) of bevacizumab (BV)-treated pts with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 702-702.	1.6	0
82	Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.. Journal of Clinical Oncology, 2015, 33, 2531-2531.	1.6	0
83	Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.. Journal of Clinical Oncology, 2015, 33, 11024-11024.	1.6	0
84	Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, e14087-e14087.	1.6	0
85	A phase 1b study of ruxolitinib (Rux) + gemcitabine (G) ± nab-paclitaxel (N) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 439-439.	1.6	0
86	NCI 9922: Phase 2 study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM).. Journal of Clinical Oncology, 2017, 35, TPS9592-TPS9592.	1.6	0
87	Evaluation of clinical outcomes by analysis of mutations in tumor tissue and circulating plasma DNA using next-generation sequencing (NGS) from STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, 11510-11510.	1.6	0